The global critical limb ischemia treatment market size is calculated at USD 5.51billion in 2025 and is forecasted to reach around USD 10.41 billion by 2034, accelerating at a CAGR of 7.35% from 2025 to 2034. The North America critical limb ischemia treatment market size surpassed USD 2.05 billion in 2024 and is expanding at a CAGR of 7.48% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Critical Limb Ischemia Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Critical Limb Ischemia Treatment Market, by Treatment
8.1.1. Medication
8.1.1.1. Market Revenue and Forecast
9.1. Critical Limb Ischemia Treatment Market, by Devices
9.1.1. Embolic Protection Devices
9.1.1.1. Market Revenue and Forecast
9.1.2. Peripheral Dilatation System
9.1.2.1. Market Revenue and Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment
10.1.2. Market Revenue and Forecast, by Devices
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment
10.1.3.2. Market Revenue and Forecast, by Devices
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment
10.1.4.2. Market Revenue and Forecast, by Devices
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment
10.2.2. Market Revenue and Forecast, by Devices
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment
10.2.3.2. Market Revenue and Forecast, by Devices
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment
10.2.4.2. Market Revenue and Forecast, by Devices
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment
10.2.5.2. Market Revenue and Forecast, by Devices
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment
10.2.6.2. Market Revenue and Forecast, by Devices
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment
10.3.2. Market Revenue and Forecast, by Devices
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment
10.3.3.2. Market Revenue and Forecast, by Devices
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment
10.3.4.2. Market Revenue and Forecast, by Devices
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment
10.3.5.2. Market Revenue and Forecast, by Devices
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment
10.3.6.2. Market Revenue and Forecast, by Devices
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment
10.4.2. Market Revenue and Forecast, by Devices
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment
10.4.3.2. Market Revenue and Forecast, by Devices
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment
10.4.4.2. Market Revenue and Forecast, by Devices
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment
10.4.5.2. Market Revenue and Forecast, by Devices
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment
10.4.6.2. Market Revenue and Forecast, by Devices
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment
10.5.2. Market Revenue and Forecast, by Devices
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment
10.5.3.2. Market Revenue and Forecast, by Devices
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment
10.5.4.2. Market Revenue and Forecast, by Devices
11.1. Boston Scientific Corporation
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pluristem Therapeutics Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Micro Medical Solutions
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Cesca Therapeutics Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Cardiovascular Systems, Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Abbott Laboratories
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. LimFlow SA
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Rexgenero Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample